This review has discussed the relevance of considering the gut microbiota in the treatment of BC patients—in particular, HER2+ tumors, for which the immune system is being increasingly implicated as a mediator of treatment efficacy and as a predictive biomarker. The gene discussed is ERBB2; the disease is breast cancer.